Market Place
Sourcing Support
Clinical Data On Salarius’ Seclidemstat In MDS And CMML Presented At EHA 2024
17 Jun 2024 //
GLOBENEWSWIRE
Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock Split
12 Jun 2024 //
GLOBENEWSWIRE
Salarius Reports Fourth Quarter and Full Year 2023 Financial Results
22 Mar 2024 //
GLOBENEWSWIRE
Salarius Provides Update on Review Process to Support Seclidemstat Trials
22 Feb 2024 //
GLOBENEWSWIRE
Salarius Issued U.S. Patent for Next-Generation Targeted Protein Degraders
16 Jan 2024 //
GLOBENEWSWIRE
Investigator-initiated Phase 1/2 Clinical Trial Using Salarius` Seclidemstat to Treat Hematologic Cancers
03 Jan 2024 //
GLOBENEWSWIRE
Salarius Completes FDA Meeting for Seclidemstat Sarcoma Development Program
07 Nov 2023 //
GLOBENEWSWIRE
Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results
10 Aug 2023 //
GLOBENEWSWIRE
Cash-strapped Salarius lays off over 50% of staff, mulls options
10 Aug 2023 //
FIERCE BIOTECH
Salarius Announces Plans to Explore Measures to Extend its Resources
08 Aug 2023 //
GLOBENEWSWIRE
Salarius Receives FDA Clearance of SP-3164 IND application to Begin Ph 1 Trial
11 Jul 2023 //
GLOBENEWSWIRE
Salarius Presents SP-3164 Targeted Protein Degrader Preclinical Data
12 Jun 2023 //
GLOBENEWSWIRE
Salarius Pharmaceuticals Announces Closing of $6 Million Private Placementles
16 May 2023 //
GLOBENEWSWIRE
Salarius Announces $6M Private Placement Priced At-the-Market Under Nasdaq Rules
12 May 2023 //
GLOBENEWSWIRE
Salarius Pharmaceuticals Reports First Quarter 2023 Financial Results
11 May 2023 //
GLOBENEWSWIRE
FDA ends clinical hold for Salarius’s Phase I/II pediatric cancer trial
10 May 2023 //
CLINICAL TRIALS ARENA
FDA frees Salarius’ rare cancer asset from clinical hold
10 May 2023 //
FIERCE BIOTECH
FDA Removes Partial Clinical Hold on Salarius Pharma™ Phase 1/2 Clinical Trial
09 May 2023 //
GLOBENEWSWIRE
Salarius Reports No Adverse Safety Signals from Two Good Laboratory SP-3164
01 May 2023 //
GLOBENEWSWIRE
Salarius Pharmaceuticals Presents Compelling Data in Two SP-3164
20 Apr 2023 //
GLOBENEWSWIRE
Salarius to Present at Diamond Equity Research Emerging Growth Invitational Conference
04 Apr 2023 //
GLOBENEWSWIRE
Salarius Pharma Reports Fourth Quarter and Full Year 2022 Financial Results
27 Mar 2023 //
GLOBENEWSWIRE
Salarius Announces Abstracts Accepted for Presentation at American Association
15 Mar 2023 //
GLOBENEWSWIRE
Salarius to Present In Vitro Data on Seclidemstat in Small Cell Lung Cancer
07 Mar 2023 //
GLOBENEWSWIRE
Salarius Pharmaceuticals Receives $1.48 Million from the Cancer Prevention
16 Feb 2023 //
GLOBENEWSWIRE
Salarius Presents SP-3164 Preclinical Data at Glue Drug Development Summit
27 Jan 2023 //
GLOBENEWSWIRE
Salarius to Present SP-3164 Targeted Protein Degrader Preclinical Data
19 Jan 2023 //
GLOBENEWSWIRE
Salarius Pharma Announces Issuance of New U.S. Patent for Next-Generation
05 Jan 2023 //
GLOBENEWSWIRE
Salarius Presents SP-3164 Data Demonstrating Activity in Lymphoma Models
13 Dec 2022 //
GLOBENEWSWIRE
Investigators Present Data on Salarius’s Seclidemstat at ASH
13 Dec 2022 //
GLOBENEWSWIRE
Salarius to Hold Conference Call to Discuss Recent Clinical and Preclinical Data
08 Dec 2022 //
GLOBENEWSWIRE
Salarius Pharma sees withdrawals, 3 of 13 patient responders in sarcoma trial
03 Dec 2022 //
ENDPTS
Salarius Pharma Announces Interim Results from Phase 1/2 Trial of Seclidemstat
01 Dec 2022 //
GLOBENEWSWIRE
Salarius Pharmaceuticals Announces Presentations at the 2022 American Society
03 Nov 2022 //
GLOBENEWSWIRE
Salarius Presents Favorable Preclinical Data on SP-3164 at Annual Conference
27 Oct 2022 //
GLOBENEWSWIRE
Salarius to Present SP-3164 at Annual Targeted Protein Degradation Conference
19 Oct 2022 //
GLOBENEWSWIRE
Salarius Announces Pause in Patient Enrollment in Ph1/2 Trial of Seclidemstat
19 Oct 2022 //
PRESS RELEASE
Salarius Pharmaceuticals Announces 1-for-25 Reverse Stock Split
14 Oct 2022 //
GLOBENEWSWIRE
Salarius Pharmaceuticals to Present at the 2022 Ladenburg Thalmann
20 Sep 2022 //
GLOBENEWSWIRE
Salarius Adds 2 Mayo Clinic Sites to Ongoing Phase 1/2 Trial of Seclidemstat
22 Aug 2022 //
GLOBENEWSWIRE
Salarius Pharmaceuticals Reports Second Quarter 2022 Financial Results
08 Aug 2022 //
GLOBENEWSWIRE
Salarius Pharma Adds Seattle Cancer Care Alliance and Oregon Health & Sciences
04 Aug 2022 //
GLOBENEWSWIRE
Salarius Pharmaceuticals and VolitionRx Enter into R&D Collaboration Agreement
02 Aug 2022 //
GLOBENEWSWIRE
Salarius Pharma to Host Second Quarter 2022 Financial Results
29 Jul 2022 //
GLOBENEWSWIRE
Salarius Pharmaceuticals to Participate in BIO International Convention 2022
09 Jun 2022 //
GLOBENEWSWIRE
Salarius Pharma to Present at H.C. Wainwright Global Investment Conference
18 May 2022 //
GLOBENEWSWIRE
Salarius Pharmaceuticals Completes SP-3164 Pre-Investigational New Drug Meeting
11 May 2022 //
GLOBENEWSWIRE
Salarius Pharmaceuticals to Report First Quarter 2022 Financial Results
05 May 2022 //
GLOBENEWSWIRE
Salarius Pharmaceuticals, Inc. Announces $2.3 Million Registered Direct Offering
22 Apr 2022 //
GLOBENEWSWIRE
Salarius Pharma Reports Q4 and FY 2021 Financial Results
10 Mar 2022 //
GLOBENEWSWIRE
Salarius Pharma to Report Q4 and Full-Year 2021 Financial Results
03 Mar 2022 //
GLOBENEWSWIRE
Salarius Pharmaceuticals to Participate in 2022 BIO CEO & Investor Conference
08 Feb 2022 //
GLOBENEWSWIRE
Salarius Pharma to AcquireTargeted Protein Degradation Portfolio from DeuteRx
13 Jan 2022 //
GLOBENEWSWIRE
Salarius Pharma to Present at Various Conferences
06 Jan 2022 //
GLOBENEWSWIRE
Salarius Pharmaceuticals Achieves Dosing Milestone in Ongoing Phase 1/2
29 Dec 2021 //
GLOBENEWSWIRE
Salarius Achieves Dosing Milestone in Ongoing Ph 1/2 Sarcoma Trial
29 Dec 2021 //
YAHOO
Salarius Pharmaceuticals to Participate in Annual Benchmark Company Discovery
29 Nov 2021 //
GLOBENEWSWIRE
Salarius Reports Q3 2021 Financial Results, Highlights Recent Company Progress
04 Nov 2021 //
GLOBENEWSWIRE
Salarius Pharmaceuticals to Report Third Quarter 2021 Financial Results
26 Oct 2021 //
GLOBENEWSWIRE
Salarius Pharmaceuticals Receives $2.7 M in Payment from the Cancer
28 Sep 2021 //
GLOBENEWSWIRE
